403 related articles for article (PubMed ID: 10516779)
21. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
22. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
[TBL] [Abstract][Full Text] [Related]
23. The natural history of early versus late disability accumulation in primary progressive MS.
Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis.
Eriksson M; Andersen O; Runmarker B
Mult Scler; 2003 Jun; 9(3):260-74. PubMed ID: 12814173
[TBL] [Abstract][Full Text] [Related]
25. Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course?
Sidhom Y; Damak M; Riahi A; Hizem Y; Mrissa R; Mhiri C; Gouider R
J Neurol Sci; 2014 Aug; 343(1-2):110-4. PubMed ID: 24980939
[TBL] [Abstract][Full Text] [Related]
26. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression.
Hohol MJ; Orav EJ; Weiner HL
Neurology; 1995 Feb; 45(2):251-5. PubMed ID: 7854521
[TBL] [Abstract][Full Text] [Related]
27. T2 lesions and rate of progression of disability in multiple sclerosis.
Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
[TBL] [Abstract][Full Text] [Related]
28. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis.
D'hooghe MB; Haentjens P; Nagels G; Garmyn M; De Keyser J
Mult Scler; 2012 Apr; 18(4):451-9. PubMed ID: 21952096
[TBL] [Abstract][Full Text] [Related]
29. Modelling the natural history of primary progressive multiple sclerosis.
Harding KE; Wardle M; Moore P; Tomassini V; Pickersgill T; Ben-Shlomo Y; Robertson NP
J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):13-9. PubMed ID: 24828900
[TBL] [Abstract][Full Text] [Related]
30. Defining reliable disability outcomes in multiple sclerosis.
Kalincik T; Cutter G; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Izquierdo G; Girard M; Duquette P; Prat A; Lugaresi A; Grand'Maison F; Grammond P; Hupperts R; Oreja-Guevara C; Boz C; Pucci E; Bergamaschi R; Lechner-Scott J; Alroughani R; Van Pesch V; Iuliano G; Fernandez-Bolaños R; Ramo C; Terzi M; Slee M; Spitaleri D; Verheul F; Cristiano E; Sánchez-Menoyo JL; Fiol M; Gray O; Cabrera-Gomez JA; Barnett M; Butzkueven H
Brain; 2015 Nov; 138(Pt 11):3287-98. PubMed ID: 26359291
[TBL] [Abstract][Full Text] [Related]
31. Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study.
Weinshenker BG; Issa M; Baskerville J
Arch Neurol; 1996 Apr; 53(4):353-8. PubMed ID: 8929158
[TBL] [Abstract][Full Text] [Related]
32. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
Lanzillo R; Di Somma C; Quarantelli M; Ventrella G; Gasperi M; Prinster A; Vacca G; Pivonello C; Orefice G; Colao A; Morra VB
Eur J Neurol; 2011 Dec; 18(12):1402-6. PubMed ID: 21585623
[TBL] [Abstract][Full Text] [Related]
33. Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.
Block VJ; Lizée A; Crabtree-Hartman E; Bevan CJ; Graves JS; Bove R; Green AJ; Nourbakhsh B; Tremblay M; Gourraud PA; Ng MY; Pletcher MJ; Olgin JE; Marcus GM; Allen DD; Cree BA; Gelfand JM
J Neurol; 2017 Feb; 264(2):316-326. PubMed ID: 27896433
[TBL] [Abstract][Full Text] [Related]
34. Long-term evolution of multiple sclerosis disability in the treatment era.
; Cree BA; Gourraud PA; Oksenberg JR; Bevan C; Crabtree-Hartman E; Gelfand JM; Goodin DS; Graves J; Green AJ; Mowry E; Okuda DT; Pelletier D; von Büdingen HC; Zamvil SS; Agrawal A; Caillier S; Ciocca C; Gomez R; Kanner R; Lincoln R; Lizee A; Qualley P; Santaniello A; Suleiman L; Bucci M; Panara V; Papinutto N; Stern WA; Zhu AH; Cutter GR; Baranzini S; Henry RG; Hauser SL
Ann Neurol; 2016 Oct; 80(4):499-510. PubMed ID: 27464262
[TBL] [Abstract][Full Text] [Related]
35. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.
Gava G; Bartolomei I; Costantino A; Berra M; Venturoli S; Salvi F; Meriggiola MC
Fertil Steril; 2014 Jul; 102(1):116-22. PubMed ID: 24794311
[TBL] [Abstract][Full Text] [Related]
36. Time between expanded disability status scale (EDSS) scores.
Zurawski J; Glanz BI; Chua A; Lokhande H; Rotstein D; Weiner H; Engler D; Chitnis T; Healy BC
Mult Scler Relat Disord; 2019 May; 30():98-103. PubMed ID: 30763908
[TBL] [Abstract][Full Text] [Related]
37. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
Mezei Z; Bereczki D; Csiba L; Csépány T
Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
[TBL] [Abstract][Full Text] [Related]
38. [Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis].
Cadavid D; Tang Y; O'Neill G
Rev Neurol; 2010 Sep; 51(6):321-9. PubMed ID: 20839168
[TBL] [Abstract][Full Text] [Related]
39. Long-term disability progression of pediatric-onset multiple sclerosis.
McKay KA; Hillert J; Manouchehrinia A
Neurology; 2019 Jun; 92(24):e2764-e2773. PubMed ID: 31092624
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]